by admin | Jul 6, 2018 | Stem Cell Therapy, COPD, Stem Cell Research
Chronic obstructive pulmonary disease (COPD) is an incurable lung disorder which makes it difficult to breathe. It includes chronic bronchitis and emphysema and is characterized by a persistent cough and mucus production. While it is not curable, it can be managed through ongoing treatment to provide patients with effective symptom control and good quality of life. There are a few key types of lung damage that can occur in COPD:
- With emphysema, the air sacs (alveoli) in the lungs are compromised. The walls of alveoli are stretched and actually cause the lungs to expand, which makes it more difficult for air to move in and out.
- In chronic bronchitis, the bronchial tubes are constantly inflamed, which limits airflow. In specific, the cilia (hair-like structures in the airways) become damaged. The airway can also become swollen and clogged.
- Refractory asthma is also marked by swelling of the bronchial airways. Even medications cannot reverse the swelling.
Here, we examine a form of COPD treatment which has been gaining attention recently.
Blood-Derived PRP
Blood-derived platelet-rich plasma (PRP) therapy is increasingly being used to treat a broad range of conditions, including sports injuries and arthritis. The procedure is performed via intravenous blood extraction. After the blood cells are harvested, they are processed, and the platelets are separated from other blood components. With the higher concentration of platelets, the treated blood is then reinserted into the patient with the hopes of reducing inflammation and speeding up the body’s healing process.
The problem with blood-derived PRP is that the evidence illustrating the effectiveness of this treatment for COPD is lacking. While some studies have been performed and suggest the treatment’s ability to support hair regrowth and reduce osteoarthritis pain, the lack of definitive proof supporting PRP therapy’s ability to make a noticeable impact on COPD has spurred criticism.
A Better Alternative
Stem cell PRP takes PRP injections a step further by mixing platelets with stem cells to treat the structural airway issues present in all forms of COPD. In numerous studies, this approach has shown promise. Coupling blood derivatives with stem cell therapy have proven effective in tissue regeneration in areas like the knee and gums, for instance. In one report, researchers concluded that the therapy “offers a promising therapeutic approach that has shown potential in diverse degenerative lung diseases” based on findings across 15 separate studies.
Through traditional PRP treatment, platelets become 5-10 times more concentrated, or 150,000- 450,000 platelets per microliter. When combined with stem cells, however, they become supercharged and platelet counts are much higher. Because research suggests that the therapeutic level for platelet count should be closer to 1,000,000 per cubic milliliter, PRP and stem cells are far more powerful than PRP alone. Moreover, PRP therapy is derived from whole blood alone, meaning it contains very few CD34+ cells – the cells commonly found in the umbilical cord and bone marrow which have the greatest self-renewal capacity – if any.
With stem cell therapy for COPD, it is guaranteed that these cells will be introduced into the body in a higher concentration. They can then promote the healing process, replacing countless cells throughout the entire body, including the lung tissue.
by admin | Oct 20, 2017 | Stem Cell Research
Xiaodong Pang and colleagues have demonstrated the successful use of human umbilical cord tissue-derived mesenchymal stem cells in the treatment of chronic discogenic low back pain. The study, published in Pain Physician, is the first study to addressing the potential of this particular treatment option for chronic discogenic low back pain.
Chronic discogenic low back pain is the leading cause of chronic low back pain, which leads to a significant amount of disability. This type of back pain does not currently have any highly successful treatment options. Generally, the pain is managed conservatively, and if all else fails, surgical fusion is undertaken. Neither of these options addresses the underlying cause of chronic discogenic low back pain and instead simply address the symptoms, offering ways to try to reverse those symptoms.
In this initial study conducted by Pang and colleagues, the researchers aimed to establish that human umbilical cord tissue-derived mesenchymal stem cells could be both feasibly and safely used in humans to treat chronic discogenic low back pain. The study, conducted at a spine center in China, focused on two patients with chronic discogenic low back pain. Both patients underwent the transplantation of the stem cells, and their back pain symptoms and lumbar function were assessed both immediately after the transplants and again two years later.
The researchers found that both the pain and the function associated with the patients’ back conditions improved immediately after the stem cell transplants. In addition to demonstrating that this particular transplant procedure was feasible, the researchers also showed that it was safe, as neither patient suffered side effects.
There are a number of reasons for which human umbilical cord tissue-derived mesenchymal stem cells may provide the benefits that these researchers observed. For instance, unlike other stem cell types, these cells have the ability to differentiate into a number of different types of cells. The results of other studies suggest that these stem cells may help with this lower back condition by altering cell activity such that less inflammation occurs.
Going forward, researchers will need to replicate the findings of this study to show that the positive effects of human umbilical cord tissue-derived mesenchymal stem cells in chronic discogenic low back pain extends to the general patient population. Further, as the mechanism by which these cells may improve the condition is not clear, research that helps to elucidate the way these cells confer their benefits will also help in the development of relevant therapeutic interventions.
To learn more about stem cell treatments click here.
Reference
Pang, X, Yang, H, & Peng, B (2014). Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain. Pain Physician. 17: E525-530.
by admin | Oct 16, 2017 | Stem Cell Research
In a study published in Cell Stem Cell, researchers helped to clarify the mechanism by which mesenchymal stem cells achieve their immunosuppressive effects. While immunosuppression is not always appealing, there are certain contexts in which suppressing the immune system is critical. These cases include patients with autoimmune disease, where their immune system begins attacking the body’s organs, as well as skin grafts, where the immune system’s reaction to new skin often leads to graft rejection.
Mesenchymal stem cells have been strategically chosen over other types of stem cells when their immunosuppressive properties are beneficial. Nonetheless, because the specific reasons that these cells lead to immunosuppression are unknown, researchers have begun to investigate potential ways that the immunosuppression occurs.
One critical factor that the researchers considered was that the immunosuppressive effects of mesenchymal stem cells may not be innate. Given that immunosuppression is not always observed when mesenchymal stem cells are employed, the researchers hypothesized that the immunosuppression may depend on the presence of other factors in combination with mesenchymal stem cells.
Nitric oxide was one factor of particular interest to the researchers because nitric oxide is known to suppress the immune system’s T cells. Nitric oxide easily diffuses across barriers and interacts with a number of important proteins, making it an attractive candidate for contributing to immunosuppression that is observed with the use of mesenchymal stem cells.
Consistent with their hypothesis, the researchers found that nitric oxide does mediate the immunosuppression achieved by mesenchymal stem cells and demonstrated a specific mechanism by which this mediation occurs. This new information improves our understanding of how mesenchymal stem cells work and will therefore also enhance our ability to strategically use these cells to achieve the therapeutic benefits for which we strive.
by admin | Oct 14, 2017 | Stem Cell Research
Research into stem cell-based therapies has increased in recent years due to observations that these types of cells can provide new avenues for treatment where other treatment options are limited. Though bone marrow mesenchymal stem cells have been the gold standard of stem cell-based therapies, there is mounting evidence that umbilical cord stem cells may offer some advantages over bone marrow mesenchymal stem cells, as well as other popular stem cell types, such as adipose tissue, periodontal ligament, and dental pulp. In a recent review in Tissue Engineering, Reine El Omar and colleagues describe the state of umbilical cord stem cell research and the potential benefits of using these cells in stem cell therapies.
According to Omar et al., umbilical cord-derived stem cells were once thought of as medical waste. However, they have now been shown to provide advantages over other stem cells in stem cell-based therapies in 3 major ways:
- Umbilical cord stem cells are easier to collect than are other stem cell types. Extracting bone marrow mesenchymal stem cells, for instance, is technically difficult and painful for donors. Umbilical cord stem cells can be painlessly collected and banked.
- Stem cells tend to proliferate more than other stem cells types. Other stem cell types have been shown to have limited proliferation and differentiation potential. Umbilical cord stem cells, on the other hand, appear to be more proliferative and differentiate longer.
- Umbilical cord stem cells are associated with less severe immune reactions than are other stem cells types. A critical aspect of the practicality of stem cells is their ability to act as therapeutic agents without causing adverse reactions. When the immune system perceives stem cells as dangerous foreign agents, the immune system can react in dangerous ways that lead to tissue damage and even death. Compared to other types of stem cells, umbilical cord stem cells appear to be associated with less severe immune reactions.
While efficacy is important for stem cell-based therapies, safety is perhaps more critical. Thus, research into how stem cells can be used therapeutically must focus not only on what therapeutic impact these cells can have but also what risks these cells pose. Future research will help to determine the safest cells to use and how those cells can best be incorporated to achieve their therapeutic goals.
Learn more about stem cell treatments here.
Reference
Omar et al. (2014). Umbilical cord mesenchymal stem cells: The new gold standard for mesenchymal stem cell-based therapies?
by admin | May 5, 2017 | Studies
Patients with multiple sclerosis suffer from an impairment in the function of specific cells of their immune system, known as T regulatory cells. The cause for the disease is not clear, and though treatments do exist, they tend to be expensive and to also carry the risk for toxic effects. To overcome the limitations of current treatment options, researchers have begun to explore the use of stem cells in the development of new treatments.
In a study recently published in the journal Oncotarget, researchers described the preliminary results of a study aimed at identifying the feasibility of using stem cells to improve the functioning of T regulatory cells in those with multiple sclerosis. Umbilical cord-derived mesenchymal stem cells were the chosen cell type for the experiment because this specific type of stem cell has been shown to affect the functioning of immune cells.
The researchers confirmed the idea that T regulatory cells are severely impaired in multiple sclerosis and were able to show that umbilical cord-derived mesenchymal stem cells could recover the functioning of the T regulatory cells of multiple sclerosis patients. Not only were there more living, active T regulatory cells in conditions that included the stem cells versus those without stem cells, but these cells also demonstrated the normal types of activities that T regulatory cells contribute to the immune system.
Previous research has established the potential for targeting T regulatory cells in the treatment of multiple sclerosis, but these studies have been conducted primarily in animal models of the disease. These newer results are the first to demonstrate the impact of umbilical cord-derived mesenchymal stem cells on immune cells of patients with multiple sclerosis.
Read more about how adult stem cell therapy can assist in the reversal of challenging symptoms and damage associated with MS here.
Reference
Yang, H. et al. (2016). Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in co-culture – a preliminary study. Oncotarget, 7: 72537-72545.
St. Petersburg, Florida
